5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells

European Journal of Medicinal Chemistry

Volumn 117, Issue , 2016, Pages 33-46

  Senkiv, Julia ^a   Finiuk, Nataliya ^a   Kaminskyy, Danylo ^b   Havrylyuk, Dmytro ^b   Wojtyra, Magdalena ^b   Kril, Iryna ^b   Gzella, Andrzej ^c   Stoika, Rostyslav ^a   Lesyk, Roman ^b  

^a INSTITUTE OF HYDROBIOLOGY   (Ukraine)

^b DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

5 Ene 4 thiazolidinones; Anticancer activity; Apoptosis; Leukemia; ROS

Indexed keywords

3 [5 [5 (2 HYDROXYPHENYL ) 3 PHENYL 4, 5 DIHYDROPYRAZOL 1 YLMETHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE 3 YL] PROPIONIC ACID ETHYL ESTER; 4 THIAZOLIDINONE DERIVATIVE; 5 [3,5 DI (4 CHLOROPHENYL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [3,5 DI (4 CHLOROPHENYL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (4 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 (NAPHTHALEN 2 YL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (PIRIDIN 3 YL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 (NAPHTHALEN 2 YL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 METHYL 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 NAPHTHALEN 2 YL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (4 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (3 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (3 TRIFLUOROMETHYL PHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (4 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (PYRIDIN 3 YL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 ETHYL 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 METHYL 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 4 THIOXOTHIAZOLIDIN 2 ONE; 5 [5 (4 CHLOROPHENYL) 3 (NAPHTALEN 2 YL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 4 THIOXOTHIAZOLIDIN 2 ONE; 5 [5 (4 CHLOROPHENYL) 3 (NAPHTHALEN 2 YL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (4 CHLOROPHENYL) 3 NAPHTHALEN 2 YL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (3 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (4 CHLOROPHENYL) 3 NAPHTHALEN 2 YL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (4 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (4 DIMETHYLAMINOPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (4 DIMETHYLAMINOPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (3 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; 5 [5 (4 METHOXYPHENYL) 3 (NAPHTHALEN 2 YL) 4,5 DIHYDROPYRAZOL 1 YLMETHYLENE] 3 (4 ACETOXYPHENYL) 2 THIOXOTHIAZOLIDIN 4 ONE; ANTILEUKEMIC AGENT; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADR CELL LINE; ANALYTIC METHOD; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CULTURE; CELL CYCLE REGULATION; CELL DEATH; CELL DIVISION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELEMENTAL ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; JURKAT CELL LINE; L1210 CELL LINE; LEUKEMIA CELL; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MAMMAL CELL; MASS SPECTROMETRY; MCF 7 CELL LINE; MITOCHONDRION; MTT ASSAY; MURINE LEUKEMIA; NONHUMAN; OVARY CARCINOMA; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; WESTERN BLOTTING; X RAY ANALYSIS; CELL CYCLE; CHEMICAL STRUCTURE; DRUG EFFECTS; HL-60 CELL LINE; LEUKEMIA; PATHOLOGY; SYNTHESIS;

APOPTOSIS; CELL CYCLE; CELL DIVISION; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; MOLECULAR STRUCTURE; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES;

EID: 84964324607     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.03.089     Document Type: Article

References (78)

1. A.C. Tripathi, S.J. Gupta, G.N. Fatima, P.K. Sonar, A. Verma, S.K. Saraf, 4-Thiazolidinones: the advances continue, Eur. J. Med. Chem. 72 (2014) 52-77.
2. R.B. Lesyk, B.S. Zimenkovsky, 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry, Curr. Org. Chem. 8 (16) (2004) 1547-1577.
3. T. Tomašic, L.P. Mašic, Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation, Expert Opin. Drug Dis. 7 (7) (2012) 549-560.
4. V.S. Jain, D.K. Vora, C.S. Ramaa, Thiazolidine-2,4-diones: progress towards multifarious applications, Bioorg. Med. Chem. 21 (7) (2013) 1599-1620.
5. A. Kryshchyshyn, D. Kaminskyy, P. Grellier, R. Lesyk, Trends in research of antitrypanosomal agents among synthetic heterocycles, Eur. J. Med. Chem. 85 (2014) 51-64.
6. V. Asati, D.K. Mahapatra, S.K. Bharti, Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents, Eur. J. Med. Chem. 87 (2014) 814-833.
7. D. Kaminskyy, D. Khyluk, O. Vasylenko, L. Zaprutko, R. Lesyk, A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates, Sci. Pharm. 79 (4) (2011) 763-777.
8. D. Kaminskyy, B. Zimenkovsky, R. Lesyk, Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives, Eur. J. Med. Chem. 44 (2009) 3627-3636.
9. D. Havrylyuk, B. Zimenkovsky, O. Vasylenko, A. Gzella, R. Lesyk, Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity, J. Med. Chem. 55 (20) (2012) 8630-8641.
10. D. Kaminskyy, I. Subtel'na, B. Zimenkovsky, O. Karpenko, A. Gzella, R. Lesyk, Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5H)-one derivatives, Med. Chem. (Shariqah UAE) 11 (6) (2015) 517-530.
11. G. Revelant, S. Huber-Villaume, S. Dunand, G. Kirsch, H. Schohn, S. Hesse, Synthesis and biological evaluation of novel 2-heteroarylimino-1,3-thiazolidin-4-ones as potential anti-tumor agents, Eur. J. Med. Chem. 94 (2015) 102-112.
12. B.Z. Ahn, D.E. Sok, Michael acceptors as a tool for anticancer drug design, Curr. Pharm. Des. 2 (3) (1996) 247-262.
13. J.B. Baell, G.A. Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem. 53 (2010) 2719-2740.
14. T. Mendgen, C. Steuer, C.D. Klein, Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry, J. Med. Chem. 55 (2) (2012) 743-753.
15. H.J. Forman, K.J.A. Davies, F. Ursini, How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo, Free Rad. Biol. Med. 66 (2014) 24-35.
16. J.C.W. Hildyard, C. Ämmälä, I.D. Dukes, S.A. Thomson, A.P. Halestrap, Identification and characterization of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier, BBA Bioenerg. 1707 (2-3) (2005) 221-230.
17. J.B. Baell, Observations on screening-based research and some concerning trends in the literature, Future Med. Chem. 2 (10) (2010) 1529-1546.
18. B. Meunier, Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 41 (1) (2008) 69-77.
19. Q. Zhang, H. Zhou, S. Zhai, B. Yan, Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities, Curr. Pharm. Des. 16 (16) (2010) 1826-1842.
20. D. Havrylyuk, B. Zimenkovsky, R. Lesyk, Synthesis, biological activity of thiazolidinones bearing indoline moiety and isatin based hybrids, Mini Rev. Org. Chem. 12 (1) (2015) 66-87.
21. D. Kaminskyy, B. Bednarczyk-Cwynar, O. Vasylenko, O. Kazakova, B. Zimenkovsky, L. Zaprutko, R. Lesyk, Synthesis of new potential anticancer agents based on 4-thiazolidinone and oleanane scaffolds, Med. Chem. Res. 21 (11) (2012) 3568-3580.
22. S. Avdieiev, L. Gera, D. Havrylyuk, R.S. Hodges, R. Lesyk, V. Ribrag, Y. Vassetzky, V. Kavsan, Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds, Bioorg. Med. Chem. 22 (15) (2014) 3815-3823.
23. K. Nepali, S. Sharma, M. Sharma, P.M.S. Bedi, K.L. Dhar, Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids, Eur. J. Med. Chem. 77 (2014) 422-487.
24. D. Kaminskyy, A. Kryshchyshyn, I. Nektegayev, O. Vasylenko, P. Grellier, R. Lesyk, Isothiocoumarin-3-carboxylic acid derivatives: synthesis, anticancer and antitrypanosomal activity evaluation, Eur. J. Med. Chem. 75 (2014) 57-66.
25. A. Degterev, A. Lugovskoy, M. Cardone, B. Mulley, G. Wagner, T. Mitchison, J. Yuan, Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL, Nat. Cell Biol. 3 (2) (2001) 173-182.
26. A.A. Lugovskoy, A.I. Degterev, A.F. Fahmy, P. Zhou, J.D. Gross, J. Yuan, G. Wagner, A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors, J. Am. Chem. Soc. 124 (7) (2002) 1234-1240.
27. N.S. Cutshall, C. O'Day, M. Prezhdo, Rhodanine derivatives as inhibitors of JSP-1, Bioorg. Med. Chem. Lett. 15 (14) (2005) 3374-3379.
28. G.C. Look, J.R. Shuilck, Ch.P. Holmes, J.P. Chinn, E.M. Gordon, M.A. Gallop, The identification of cyclooxygenase-1 inhibitors from 4-thiazolidinone combinatorial library, Bioorg. Med. Chem. Lett. 6 (1996) 707-712.
29. X. Liu, H. Xie, C. Luo, L. Tong, Y. Wang, T. Prng, J. Ding, H. Jiang, H. Li, Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening, J. Med. Chem. 53 (2010) 2661-2665.
30. K.Y. Jung, R. Samadani, J. Chauhan, K. Nevels, J.L. Yap, J. Zhang, S. Worlikar, M.E. Lanning, L. Chen, M. Ensey, S. Shukla, R. Salmo, G. Heinzl, C. Gordon, T. Dukes, A.D. MacKerell Jr., P. Shapiro, S. Fletcher, Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione thatimprove selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling, Org. Biomol. Chem. 11 (2013) 3706-3732.
31. M.J. Chisamore, H.A. Wilkinson, O. Flores, J.D. Chen, Estrogen-related receptora antagonist inhibits both estrogen receptorepositive and estrogen receptorenegative breast tumor growth in mouse xenografts, Mol. Cancer Ther. 8 (3) (2009) 672-681.
32. Z. Xia, C. Knaak, J. Ma, Z.M. Beharry, C. McInnes, W. Wang, A.S. Kraft, C.D. Smith, Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases, J. Med. Chem. 52 (2009) 74-86.
33. L.T. Vassilev, C. Tovar, S. Chen, D. Knezevic, X. Zhao, H. Sun, D.C. Heimbrook, L. Chen, Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1, PNAS 103 (28) (2006) 10660-10665.
34. S. Chandrappa, C.V. Kavitha, M.S. Shahabuddin, K. Vinaya, C.A. Kumar, S.R. Ranganatha, S.C. Raghavan, K.S. Rangappa, Synthesis of 2-(5-((5-(4-chlorophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid derivatives and evaluation of their cytotoxicity and induction of apoptosis in human leukemia cells, Bioorg. Med. Chem. 17 (6) (2009) 2576-2584.
35. S. Chen, L. Chen, N.T. Le, C. Zhao, A. Sidduri, J.P. Lou, C. Michoud, L. Portland, N. Jackson, J.J. Liu, F. Konzelmann, F. Chi, C. Tovar, Q. Xiang, Y. Chen, Y. Wen, L.T. Vassilev, Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors, Bioorg. Med. Chem. Lett. 17 (8) (2007) 2134-2138.
36. A. Santamaria, R. Neef, U. Eberspächer, K. Eis, M. Husemann, D. Mumberg, S. Prechtl, V. Schulze, G. Siemeister, L. Wortmann, F.A. Barr, E.A. Nigg, Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis, Mol. Biol. Cell 18 (10) (2007) 4024-4036.
37. A. Geronikaki, P. Eleftheriou, P. Vicini, I. Alam, A. Dixit, A.K. Saxena, 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action, J. Med. Chem. 51 (2008) 5221-5228.
38. P.H. Carter, P.A. Scherle, J.A. Muckelbauer, M.E. Voss, R.Q. Liu, L.A. Thompson, A.J. Tebben, K.A. Solomon, Y.C. Lo, Z. Li, P. Strzemienski, G. Yang, N. Falahatpisheh, M. Xu, Z. Wu, N.A. Farrow, K. Ramnarayan, J. Wang, D. Rideout, V. Yalamoori, P. Domaille, D.J. Underwood, J.M. Trzaskos, S.M. Friedman, R.C. Newton, C.P. Decicco, Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-a, PNAS 98 (21) (2001) 11879-11884.
39. R. Dayam, F. Aiello, J. Deng, Y. Wu, A. Garofalo, X. Chen, N. Neamati, Discovery of small molecule integrin avb3 antagonists as novel anticancer agents, J. Med. Chem. 49 (15) (2006) 4526-4534.
40. H. Wang, D.I. Hammoudeh, A.V. Follis, B.E. Reese, J.S. Lazo, S.J. Metallo, E.V. Prochownik, Improved low molecular weight Myc-Max inhibitors, Mol. Cancer Ther. 6 (2007) 2399-2408.
41. Y. Zhang, M. Luo, Y. Zu, Y. Fu, C. Gu, W. Wang, L. Yao, T. Efferth, Dryofragin, a phloroglucinol derivative, induces apoptosis in human breast cancer MCF-7 cells through ROS-mediated mitochondrial pathway, Chem. Biol. Interact. 199 (2) (2012) 129-136.
42. F.E. Onen-Bayram, I. Durmaz, D. Scherman, J. Herscovici, R. Cetin-Atalay, A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells, Bioorg. Med. Chem. 20 (17) (2012) 5094-5102.
43. W. Li, Z. Wang, V. Gududuru, B. Zbytek, A.T. Slominski, J.T. Dalton, D.D. Miller, Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma, Anticancer Res. 27 (2) (2007) 883-888.
44. V.V. Chumak, M.R. Fil, R.R. Panchuk, B.S. Zimenkovsky, D.Y. Havrylyuk, R.B. Lesyk, R.S. Stoika, Study of antineoplastic action of novel isomeric derivatives of 4-thiazolidinone, Ukr. Biochem. J. 86 (6) (2014) 96-105.
45. K.S.S. Kumar, A. Hanumappa, M. Vetrivel, M. Hegde, Y.R. Girish, T.R. Byregowda, S. Rao, S.C. Raghavan, K.S. Rangappa, Antiproliferative and tumor inhibitory studies of 2,3-disubstituted 4-thiazolidinone derivatives, Bioorg. Med. Chem. Lett. 25 (17) (2015) 3616-3620.
46. Y. Miyata, X. Li, H.F. Lee, U.K. Jinwal, S.R. Srinivasan, S.P. Seguin, Z.T. Young, J.L. Brodsky, C.A. Dickey, D. Sun, J.E. Gestwicki, Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels, ACS Chem. Neurosci. 4 (6) (2013) 930-939.
47. F. Wang, Z. Liu, J. Wang, J. Tao, P. Gong, X. Bao, Y. Zhao, Y. Wang, The interaction of 4-thiazolidinone derivatives containing indolin-2-one moiety with P-glycoprotein studied using K562 cell lines, Eur. J. Med. Chem. 101 (2015) 126-132.
48. F. Teraishi, S.H. Wu, J. Sasaki, L.D. Zhang, H.B. Zhu, J.J. Davis, B.L. Fang, Pglycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene],-2-(phenylamino)-4(5H)-thiazolone], J. Pharmacol. Exp. Ther. 314 (2005) 355-362.
49. A.M. Senderowicz, The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01, Oncologist 7 (3) (2002) 12-19.
50. H. Chen, Y.H. Fan, A. Natarajan, Y. Guo, J. Iyasere, F. Harbinski, L. Luus, W. Christ, H. Aktas, J.A. Halperin, Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation, Bioorg. Med. Chem. Lett. 14 (21) (2004) 5401-5405.
51. D. Havrylyuk, B. Zimenkovsky, O. Karpenko, P. Grellier, R. Lesyk, Synthesis of pyrazolineethiazolidinone hybrids with trypanocidal activity, Eur. J. Med. Chem. 85 (2014) 245-254.
52. B.A. Bhat, S. Ponnala, D.P. Sahu, P. Tiwari, B.K. Tripathi, A.K. Srivastava, Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives, Bioorg. Med. Chem. 12 (22) (2004) 5857-5864.
53. H. Zhou, S. Wu, S. Zhai, A. Liu, Y. Sun, R. Li, Y. Zhang, S. Ekins, P.W. Swaan, B. Fang, B. Zhang, B. Yan, Design, synthesis, cytoselective toxicity, structureeactivity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells, J. Med. Chem. 51 (5) (2008) 1242-1251.
54. S. Wu, W. Guo, F. Teraishi, J. Pang, K. Kaluarachchi, L. Zhang, J. Davis, F. Dong, B. Yan, B. Fang, Anticancer activity of 5-benzylidene-2-phenylimino-1,3-thiazolidin-4-one (BPT) analogs, Med. Chem. 2 (6) (2006) 597-605.
55. C.P. Lo, W.J. Croxall, 5-Alkoxymethylenerhodanines and their reactions with rhodanines, J. Am. Chem. Soc. 76 (1954) 4166-4169.
56. D. Atamanyuk, B. Zimenkovsky, V. Atamanyuk, R. Lesyk, 5-Ethoxymethylidene-4-thioxo-2-thiazolidinone as versatile building block for novel biorelevant small molecules with thiopyrano[2,3-d][1,3]thiazole core, Synth. Commun. 44 (2) (2014) 237-244.
57. X. Li, P. Fang, J. Mai, E.T. Choi, H. Wang, X.F. Yang, Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers, J. Hematol. Oncol. 6 (2013) 19.
58. M.L. Heaney, J.R. Gardner, N. Karasavvas, D.W. Golde, D.A. Scheinberg, E.A. Smith, O.A. O'Connor, Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs, J. Cancer Res. 68 (19) (2008) 8031-8038.
59. T. Abbas, A. Dutta, p21 in cancer: intricate networks and multiple activities, Nat. Rev. Cancer 9 (6) (2009) 400-414.
60. P. Heffeter, M.A. Jakupec, W. Korner, P. Chiba, C. Pirker, R. Dornetshuber, L. Elbling, H. Sutterluty, M. Micksche, B.K. Keppler, W. Berger, Multidrugresistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24), Biochem. Pharmacol. 73 (2007) 1873-1886.
61. A.C. Rego, C.R. Oliveira, Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases, Neurochem. Res. 28 (10) (2003) 1563-1574.
62. B. Huppertz, M. Kadyrov, J.C. Kingdom, Apoptosis and its role in the trophoblast, Am. J. Obstet. Gynecol. 195 (2006) 29-39.
63. B.T. Moorthy, S. Ravi, M. Srivastava, K.K. Chiruvella, H. Hemlal, O. Joy, S.C. Raghavan, Novel rhodanine derivatives induce growth inhibition followed by apoptosis, Bioorg. Med. Chem. Lett. 20 (21) (2010) 6297-6301.
64. Z. Ren, N. Yang, C. Ji, J. Zheng, T. Wang, Y. Liu, P. Zuo, Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice, Neuropharmacol 93 (2015) 209-218.
65. A.A. Geronikaki, E.P. Pitta, K.S. Liaras, Thiazoles and thiazolidinones as antioxidants, Curr. Med. Chem. 20 (36) (2013) 4460-4480.
66. L. Crascè, P. Vicini, M. Incerti, V. Cardile, S. Avondo, A. Panico, 2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction, Bioorg. Med. Chem. 23 (7) (2015) 1551-1556.
67. W. Liu, A. Bulgaru, M. Haigentz, C.A. Stein, R. Perez-Soler, S. Mani, The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics, Curr. Med. Chem. 3 (2003) 217-223.
68. R. Kim, K. Tanabe, Y. Uchida, M. Emi, H. Inoue, T. Toge, Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy, Cancer Chemother. Pharmacol. 50 (5) (2002) 343-352.
69. Y. Tsujimoto, S. Shimizu, VDAC regulation by the Bcl-2 family of proteins, Cell Death Differ. 7 (12) (2000) 1174-1181.
70. H. Nakagami, R. Morishita, K. Yamamoto, Y. Taniyama, M. Aoki, K. Matsumoto, T. Nakamura, Y. Kaneda, M. Horiuchi, T. Ogihara, Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and Akt in endothelial cells, Hypertension 37 (2001) 581-586.
71. K.H. Kang, W.H. Kim, K.H. Choi, p21 promotes ceramide induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells, Exp. Cell Res. 253 (1999) 403-412.
72. A.L. Gartel, A.L. Tyner, The role of the cyclin-dependent kinase inhibitor p21 in apoptosis, Mol. Cancer Ther. 1 (2002) 639-649.
73. C.M. Sawai, J. Freund, P. Oh, D. Ndiaye-Lobry, J.C. Bretz, A. Strikoudis, L. Genesca, T. Trimarchi, M.A. Kelliher, M. Clark, J. Soulier, S. Chen-Kiang, I. Aifantis, Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia, Cancer Cell 22 (4) (2012) 452-465.
74. I.D. Komaritsa, S.N. Baranov, A.P. Grishchuk, 4-Thiazolidines, derivatives an analogs, Chem. Heterocycl. Compd. 3 (1967) 533-534.
75. E. Palaska, V. Aytemir, I.T. Uzbay, D. Erol, Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines, Eur. J. Med. Chem. 36 (2001) 539-543.
76. G. Sheldrick, A short history of SHELX, Acta Crystallogr. Sect. A 64 (2008) 112-122.
77. L.J. Farrugia, WinGX and ORTEP for Windows: an update, J. Appl. Crystallogr. 45 (2012) 849-854.
78. X. Liu, Y.G. Zu, Y.J. Fu, L.P. Yao, C.B. Gu, W. Wang, T. Efferth, Antimicrobial activity and cytotoxicity towards cancer cells of Melaleuca alternifolia (tea tree) oil, Eur. Food Res. Technol. 229 (2009) 247-253.